Drug Profile
Research programme: CNS disorders therapeutics - Astellas Pharma
Alternative Names: ASP5854; FR 194921; FR 260010Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Small molecules
- Mechanism of Action Adenosine A1 receptor antagonists; Adenosine A2A receptor antagonists; Serotonin 2C receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Cognition disorders; Dementia; Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anxiety-disorders in Japan (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cognition-disorders in Japan (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in Japan (PO)